Last reviewed 2026-04-23 · How we verify

LASW1510

LASW1510 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.

LASW1510 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells. Used for Atopic dermatitis, Psoriasis.

At a glance

Mechanism of action

PDE4 inhibition increases intracellular cAMP levels in inflammatory cells such as neutrophils, macrophages, and T cells, leading to suppression of pro-inflammatory cytokine and chemokine release. This mechanism is intended to reduce excessive inflammatory responses in autoimmune and inflammatory diseases. The drug is being developed by Almirall for dermatological and systemic inflammatory conditions.

Approved indications

• Atopic dermatitis
• Psoriasis

Common side effects

• Nausea
• Diarrhea
• Headache
• Upper respiratory tract infection

Key clinical trials

• Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.